1 Study Coverage
    1.1 Antidiabetic SGLT-2 Inhibitor Product Introduction
    1.2 Market by Type
        1.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Canagliflozin
        1.2.3 Empagliflozin
        1.2.4 Dapagliflozin
        1.2.5 Other
    1.3 Market by Application
        1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Estimates and Forecasts 2017-2028
    2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Estimates and Forecasts 2017-2028
    2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Antidiabetic SGLT-2 Inhibitor Sales by Region
        2.4.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022)
        2.4.2 Global Sales Antidiabetic SGLT-2 Inhibitor by Region (2023-2028)
    2.5 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region
        2.5.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022)
        2.5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers
        3.1.1 Global Top Antidiabetic SGLT-2 Inhibitor Manufacturers by Sales (2017-2022)
        3.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antidiabetic SGLT-2 Inhibitor in 2021
    3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers
        3.2.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2017-2022)
        3.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Antidiabetic SGLT-2 Inhibitor Revenue in 2021
    3.3 Global Antidiabetic SGLT-2 Inhibitor Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Antidiabetic SGLT-2 Inhibitor Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type
        4.1.1 Global Antidiabetic SGLT-2 Inhibitor Historical Sales by Type (2017-2022)
        4.1.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Sales by Type (2023-2028)
        4.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    4.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type
        4.2.1 Global Antidiabetic SGLT-2 Inhibitor Historical Revenue by Type (2017-2022)
        4.2.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    4.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type
        4.3.1 Global Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2022)
        4.3.2 Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application
        5.1.1 Global Antidiabetic SGLT-2 Inhibitor Historical Sales by Application (2017-2022)
        5.1.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Sales by Application (2023-2028)
        5.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application
        5.2.1 Global Antidiabetic SGLT-2 Inhibitor Historical Revenue by Application (2017-2022)
        5.2.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    5.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application
        5.3.1 Global Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2022)
        5.3.2 Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Antidiabetic SGLT-2 Inhibitor Market Size by Type
        6.1.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
        6.1.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
    6.2 North America Antidiabetic SGLT-2 Inhibitor Market Size by Application
        6.2.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
        6.2.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
    6.3 North America Antidiabetic SGLT-2 Inhibitor Market Size by Country
        6.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
        6.3.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Type
        7.1.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
        7.1.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
    7.2 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Application
        7.2.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
        7.2.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
    7.3 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Country
        7.3.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
        7.3.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Type
        8.1.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
        8.1.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
    8.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Application
        8.2.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
        8.2.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
    8.3 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Region
        8.3.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2028)
        8.3.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 China Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
9 Latin America
    9.1 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Type
        9.1.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
        9.1.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
    9.2 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Application
        9.2.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
        9.2.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
    9.3 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Country
        9.3.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
        9.3.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Type
        10.1.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
    10.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Application
        10.2.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
    10.3 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Country
        10.3.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Pfizer
        11.1.1 Pfizer Corporation Information
        11.1.2 Pfizer Overview
        11.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Pfizer Recent Developments
    11.2 AstraZeneca
        11.2.1 AstraZeneca Corporation Information
        11.2.2 AstraZeneca Overview
        11.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 AstraZeneca Recent Developments
    11.3 Johnson & Johnson
        11.3.1 Johnson & Johnson Corporation Information
        11.3.2 Johnson & Johnson Overview
        11.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Johnson & Johnson Recent Developments
    11.4 GlaxoSmithKline
        11.4.1 GlaxoSmithKline Corporation Information
        11.4.2 GlaxoSmithKline Overview
        11.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 GlaxoSmithKline Recent Developments
    11.5 Merck & Co
        11.5.1 Merck & Co Corporation Information
        11.5.2 Merck & Co Overview
        11.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Merck & Co Recent Developments
    11.6 Eli Lilly
        11.6.1 Eli Lilly Corporation Information
        11.6.2 Eli Lilly Overview
        11.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Eli Lilly Recent Developments
    11.7 Sanofi
        11.7.1 Sanofi Corporation Information
        11.7.2 Sanofi Overview
        11.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Sanofi Recent Developments
    11.8 Takeda Pharmaceuticals
        11.8.1 Takeda Pharmaceuticals Corporation Information
        11.8.2 Takeda Pharmaceuticals Overview
        11.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Takeda Pharmaceuticals Recent Developments
    11.9 Novo Nordisk
        11.9.1 Novo Nordisk Corporation Information
        11.9.2 Novo Nordisk Overview
        11.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Novo Nordisk Recent Developments
    11.10 Servier Laboratories
        11.10.1 Servier Laboratories Corporation Information
        11.10.2 Servier Laboratories Overview
        11.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Servier Laboratories Recent Developments
    11.11 Boehringer Ingelheim
        11.11.1 Boehringer Ingelheim Corporation Information
        11.11.2 Boehringer Ingelheim Overview
        11.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Boehringer Ingelheim Recent Developments
    11.12 Bristol-Myers Squibb
        11.12.1 Bristol-Myers Squibb Corporation Information
        11.12.2 Bristol-Myers Squibb Overview
        11.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Bristol-Myers Squibb Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Antidiabetic SGLT-2 Inhibitor Industry Chain Analysis
    12.2 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
    12.4 Antidiabetic SGLT-2 Inhibitor Sales and Marketing
        12.4.1 Antidiabetic SGLT-2 Inhibitor Sales Channels
        12.4.2 Antidiabetic SGLT-2 Inhibitor Distributors
    12.5 Antidiabetic SGLT-2 Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
    13.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
    13.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
    13.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
14 Key Findings in The Global Antidiabetic SGLT-2 Inhibitor Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Canagliflozin
    Table 3. Major Manufacturers of Empagliflozin
    Table 4. Major Manufacturers of Dapagliflozin
    Table 5. Major Manufacturers of Other
    Table 6. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022) & (K Pcs)
    Table 9. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
    Table 10. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2023-2028) & (K Pcs)
    Table 11. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2023-2028)
    Table 12. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2017-2022)
    Table 14. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2023-2028)
    Table 16. Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 17. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers (2017-2022)
    Table 18. Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2017-2022)
    Table 20. Antidiabetic SGLT-2 Inhibitor Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 21. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2021)
    Table 23. Antidiabetic SGLT-2 Inhibitor Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Antidiabetic SGLT-2 Inhibitor Product Offered
    Table 25. Date of Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 28. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
    Table 29. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2017-2022)
    Table 30. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2023-2028)
    Table 31. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2017-2022)
    Table 34. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2023-2028)
    Table 35. Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2022) & (USD/Pcs)
    Table 36. Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 37. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
    Table 38. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
    Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2017-2022)
    Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2023-2028)
    Table 41. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2017-2022)
    Table 44. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2023-2028)
    Table 45. Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2022) & (USD/Pcs)
    Table 46. Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 47. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 48. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
    Table 49. North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
    Table 52. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
    Table 53. North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 56. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
    Table 57. North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 60. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
    Table 61. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
    Table 64. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
    Table 65. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 68. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
    Table 69. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 72. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
    Table 73. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
    Table 76. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
    Table 77. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022) & (K Pcs)
    Table 80. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2023-2028) & (K Pcs)
    Table 81. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 84. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
    Table 85. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
    Table 88. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
    Table 89. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 92. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
    Table 93. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 96. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
    Table 97. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
    Table 100. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
    Table 101. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 104. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
    Table 105. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
    Table 107. Pfizer Corporation Information
    Table 108. Pfizer Description and Major Businesses
    Table 109. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. Pfizer Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Pfizer Recent Developments
    Table 112. AstraZeneca Corporation Information
    Table 113. AstraZeneca Description and Major Businesses
    Table 114. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. AstraZeneca Recent Developments
    Table 117. Johnson & Johnson Corporation Information
    Table 118. Johnson & Johnson Description and Major Businesses
    Table 119. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 120. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Johnson & Johnson Recent Developments
    Table 122. GlaxoSmithKline Corporation Information
    Table 123. GlaxoSmithKline Description and Major Businesses
    Table 124. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 125. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. GlaxoSmithKline Recent Developments
    Table 127. Merck & Co Corporation Information
    Table 128. Merck & Co Description and Major Businesses
    Table 129. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 130. Merck & Co Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Merck & Co Recent Developments
    Table 132. Eli Lilly Corporation Information
    Table 133. Eli Lilly Description and Major Businesses
    Table 134. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 135. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. Eli Lilly Recent Developments
    Table 137. Sanofi Corporation Information
    Table 138. Sanofi Description and Major Businesses
    Table 139. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 140. Sanofi Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. Sanofi Recent Developments
    Table 142. Takeda Pharmaceuticals Corporation Information
    Table 143. Takeda Pharmaceuticals Description and Major Businesses
    Table 144. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 145. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Takeda Pharmaceuticals Recent Developments
    Table 147. Novo Nordisk Corporation Information
    Table 148. Novo Nordisk Description and Major Businesses
    Table 149. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 150. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. Novo Nordisk Recent Developments
    Table 152. Servier Laboratories Corporation Information
    Table 153. Servier Laboratories Description and Major Businesses
    Table 154. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 155. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Servier Laboratories Recent Developments
    Table 157. Boehringer Ingelheim Corporation Information
    Table 158. Boehringer Ingelheim Description and Major Businesses
    Table 159. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 160. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. Boehringer Ingelheim Recent Developments
    Table 162. Bristol-Myers Squibb Corporation Information
    Table 163. Bristol-Myers Squibb Description and Major Businesses
    Table 164. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 165. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
    Table 166. Bristol-Myers Squibb Recent Developments
    Table 167. Key Raw Materials Lists
    Table 168. Raw Materials Key Suppliers Lists
    Table 169. Antidiabetic SGLT-2 Inhibitor Distributors List
    Table 170. Antidiabetic SGLT-2 Inhibitor Customers List
    Table 171. Antidiabetic SGLT-2 Inhibitor Market Trends
    Table 172. Antidiabetic SGLT-2 Inhibitor Market Drivers
    Table 173. Antidiabetic SGLT-2 Inhibitor Market Challenges
    Table 174. Antidiabetic SGLT-2 Inhibitor Market Restraints
    Table 175. Research Programs/Design for This Report
    Table 176. Key Data Information from Secondary Sources
    Table 177. Key Data Information from Primary Sources
List of Figures
    Figure 1. Antidiabetic SGLT-2 Inhibitor Product Picture
    Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2021 & 2028
    Figure 3. Canagliflozin Product Picture
    Figure 4. Empagliflozin Product Picture
    Figure 5. Dapagliflozin Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2021 & 2028
    Figure 8. Hospitals
    Figure 9. Clinics
    Figure 10. Other
    Figure 11. Antidiabetic SGLT-2 Inhibitor Report Years Considered
    Figure 12. Global Antidiabetic SGLT-2 Inhibitor Sales 2017-2028 (K Pcs)
    Figure 13. Global Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Antidiabetic SGLT-2 Inhibitor Revenue 2017-2028 (US$ Million)
    Figure 15. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 16. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
    Figure 17. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2023-2028)
    Figure 18. North America Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
    Figure 19. North America Antidiabetic SGLT-2 Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Europe Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
    Figure 21. Europe Antidiabetic SGLT-2 Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
    Figure 23. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Latin America Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
    Figure 25. Latin America Antidiabetic SGLT-2 Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
    Figure 27. Middle East & Africa Antidiabetic SGLT-2 Inhibitor Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. The Antidiabetic SGLT-2 Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 29. The Top 5 and 10 Largest Manufacturers of Antidiabetic SGLT-2 Inhibitor in the World: Market Share by Antidiabetic SGLT-2 Inhibitor Revenue in 2021
    Figure 30. Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 31. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    Figure 32. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 33. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    Figure 34. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 35. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    Figure 36. North America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 37. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    Figure 38. North America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 39. North America Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2017-2028)
    Figure 40. North America Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2017-2028)
    Figure 41. U.S. Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 42. Canada Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 43. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    Figure 44. Europe Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 45. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    Figure 46. Europe Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 47. Europe Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2017-2028)
    Figure 48. Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2017-2028)
    Figure 49. Germany Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 50. France Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 51. U.K. Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 52. Italy Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 53. Russia Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 54. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Share by Region (2017-2028)
    Figure 59. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue Share by Region (2017-2028)
    Figure 60. China Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 61. Japan Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 62. South Korea Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 63. India Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 64. Australia Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 65. China Taiwan Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 66. Indonesia Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 67. Thailand Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 68. Malaysia Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 69. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    Figure 70. Latin America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 71. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    Figure 72. Latin America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 73. Latin America Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2017-2028)
    Figure 74. Latin America Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2017-2028)
    Figure 75. Mexico Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 76. Brazil Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 77. Argentina Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 78. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Share by Country (2017-2028)
    Figure 83. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Share by Country (2017-2028)
    Figure 84. Turkey Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 85. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 86. UAE Antidiabetic SGLT-2 Inhibitor Revenue (2017-2028) & (US$ Million)
    Figure 87. Antidiabetic SGLT-2 Inhibitor Value Chain
    Figure 88. Antidiabetic SGLT-2 Inhibitor Production Process
    Figure 89. Channels of Distribution
    Figure 90. Distributors Profiles
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed